International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 4, April 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

A Comprehensive Review on Different Drugs Used in DSR Tablets: Quality Aspects and Physicochemical Properties

Raj A. Sharma, Gauri S. Mahajan, Nikita R. Pagare, Prem N. Sharma, Sarvesh S. Shinde, Payal K. Shelar

Shivajirao S Jondhle College of Pharmacy, Thane, Maharashtra, India.

Received: 23 February 2026 Revised: 07 March 2026 Accepted: 25 March 2026

ABSTRACT

Gastroesophageal reflux disease (GERD) is a prevalent chronic digestive disorder requiring comprehensive therapeutic management. DSR tablets, containing Domperidone and Rabeprazole in fixed-dose combination, represent a significant advancement in GERD treatment by simultaneously addressing both acid suppression and gastric motility enhancement. This comprehensive review provides an in-depth analysis of the pharmacological profiles, physicochemical properties, quality control aspects, and formulation challenges associated with DSR tablets. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and provides antiemetic effects, while Rabeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion through irreversible inhibition of H+/K+-ATPase. The review discusses the comparative advantages of these agents over alternative prokinetic drugs and PPIs, highlighting Domperidone's superior tolerability profile due to minimal central nervous system penetration and Rabeprazole's predictable pharmacokinetics with reduced CYP2C19 dependence. Formulation challenges including Domperidone's poor aqueous solubility and Rabeprazole's acid-labile nature are addressed through various technological approaches such as solid dispersion, enteric coating systems, and Multiple Unit Particulate Systems (MUPS). Quality control methodologies including HPLC, UV-spectrophotometry, and LC-MS/MS techniques for both components are comprehensively reviewed. Clinical evidence demonstrates superior efficacy of combination therapy in symptom resolution, healing rates, and quality of life improvements compared to monotherapy. The safety profile, drug interactions, contraindications, and future perspectives including novel formulation technologies, alternative combination therapies, and personalized medicine approaches are also discussed. This review serves as a comprehensive resource for pharmaceutical scientists, formulation developers, quality control professionals, and clinicians involved in the development, manufacture, and therapeutic application of DSR tablets. [1, 2, 3, 16, 23]

Keywords: DSR tablets, Domperidone, Rabeprazole, Gastroesophageal reflux disease (GERD), Proton pump inhibitor, Prokinetic agent, Fixed-dose combination, Enteric coating, Formulation challenges, Quality control, HPLC analysis, Pharmaceutical development, Combination therapy, Pharmacokinetics, Drug stability.

INTRODUCTION

Background

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder affecting millions worldwide, characterized by the retrograde flow of gastric contents into the esophagus, causing symptoms such as heartburn, regurgitation, and dyspepsia. The management of GERD requires a multifaceted approach addressing both acid suppression and gastric motility enhancement. Traditional monotherapy with proton pump inhibitors (PPIs) alone may not adequately address all symptoms, particularly those related to delayed gastric emptying and esophageal dysmotility.[16]

The development of combination formulations containing both a proton pump inhibitor and a prokinetic agent has revolutionized GERD management. DSR tablets, primarily composed of Domperidone (a dopamine D2 receptor antagonist with prokinetic properties) and Rabeprazole (a substituted benzimidazole PPI), exemplify this therapeutic advancement. These fixed-dose combinations offer synergistic benefits by simultaneously reducing gastric acid secretion and enhancing gastrointestinal motility.[23]

Rationale for Combination Therapy

The rationale for combining Domperidone and Rabeprazole stems from their complementary mechanisms of action. While Rabeprazole effectively suppresses acid production by irreversibly inhibiting the H+/K+- ATPase enzyme system in gastric parietal cells, Domperidone accelerates gastric emptying and increases lower esophageal sphincter pressure. This dual action addresses both the chemical (acid-related) and mechanical (motility-related) components of GERD pathophysiology.[14]

Clinical studies have demonstrated that combination therapy provides superior symptom relief compared to monotherapy, particularly in patients with refractory GERD or those experiencing both acid reflux and gastroparesis symptoms. The fixed-dose combination also improves patient compliance by reducing pill burden and simplifying dosing regimens.[12]

Scope of Review

This comprehensive review aims to provide an in-depth analysis of the drugs used in DSR tablets, focusing on:

- Detailed pharmacological profiles of individual components
- Physicochemical properties and their pharmaceutical implications
- Quality control aspects and analytical methods
- Formulation challenges and strategies
- Comparative analysis of different drugs in the same therapeutic class
- Clinical efficacy and safety considerations
- Future perspectives in combination therapy development[1]

Drugs Used in DSR Tablets

Domperidone

Chemical Structure and Properties

Domperidone, chemically known as 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4- piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one, is a synthetic benzimidazole derivative. Its molecular formula is C22H24ClN5O2 with a molecular weight of 425.91 g/mol.[3]

Key Physicochemical Properties:

- Appearance: White to slightly beige powder
- Melting point: 243-245°C
- Solubility: Practically insoluble in water; sparingly soluble in methanol; slightly soluble in ethanol
- pKa: 7.8 (benzimidazole nitrogen)
- Log P: 3.9 (indicating lipophilic nature)
- pH stability: Stable in acidic to neutral pH range

The poor aqueous solubility of Domperidone presents significant formulation challenges, necessitating the use of solubility enhancement techniques such as solid dispersion, complexation with cyclodextrins, or particle size reduction through

micronization.[20]

Pharmacokinetic Profile

Absorption: Domperidone is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 30-60 minutes. However, its bioavailability is low (approximately 15%) due to extensive first-pass metabolism. Food intake can slightly decrease absorption rate but does not significantly affect bioavailability.[31]

Distribution: The volume of distribution is large (approximately 5.7 L/kg), indicating extensive tissue distribution. Plasma protein binding is high (91-93%), primarily to albumin. Importantly, Domperidone does not readily cross the blood-brain barrier, which minimizes central nervous system side effects commonly associated with other dopamine antagonists.[20]

Metabolism: Domperidone undergoes extensive hepatic metabolism, primarily via CYP3A4-mediated hydroxylation and N-dealkylation. The metabolites are pharmacologically inactive.[30]

Elimination: The elimination half-life ranges from 7-9 hours following oral administration. Approximately 31% of the dose is excreted in urine and 66% in feces, primarily as metabolites.[31]

Stability Considerations

Domperidone demonstrates good stability under normal storage conditions but is susceptible to degradation under extreme pH conditions and high temperatures. Photostability studies indicate minimal degradation under normal light exposure. The drug substance should be stored in well-closed containers protected from moisture.[42]

Rabeprazole Sodium

Chemical Structure and Properties

Rabeprazole sodium, chemically 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H- benzimidazole sodium salt, is a substituted benzimidazole derivative belonging to the proton pump inhibitor class.

Molecular Information:

- Molecular formula: C18H20N3NaO3S
- Molecular weight: 381.43 g/mol
- Chemical nature: Sodium salt form of rabeprazole

Key Physicochemical Properties:

- Appearance: White to slightly yellowish crystalline powder
- Melting point: Decomposes above 140°C
- Solubility: Freely soluble in water; soluble in methanol and ethanol
- pKa: 4.9 (benzimidazole) and 1.8 (pyridine)
- pH stability: Highly unstable in acidic conditions; stable in alkaline pH
- Hygroscopicity: Moderately hygroscopic

The acid-labile nature of Rabeprazole necessitates enteric coating in solid dosage forms to prevent degradation in the acidic environment of the stomach. This presents a critical formulation challenge in DSR tablets where both immediate-release and delayed-release components must coexist.[19]

Pharmacokinetic Profile

Absorption: Following oral administration of enteric-coated formulations, Rabeprazole is rapidly absorbed from the small intestine. Peak plasma concentrations are typically achieved 2-5 hours after dosing, depending on the coating system. Unlike some other PPIs, Rabeprazole absorption is not significantly affected by food.[26]

Distribution: The volume of distribution at steady state is approximately 0.4 L/kg. Plasma protein binding is high (96.3%), predominantly to albumin and alpha-1-acid glycoprotein.[19]

Metabolism: Rabeprazole is extensively metabolized in the liver through both enzymatic and non-enzymatic pathways. CYP2C19 and CYP3A4 are the primary enzymes involved, though Rabeprazole demonstrates less dependence on CYP2C19 polymorphism compared to other PPIs like Omeprazole. This results in more predictable pharmacokinetics across different patient populations.[18]

Elimination: The elimination half-life is approximately 1-2 hours. Despite the short half-life, the antisecretory effect persists for 24-48 hours due to irreversible binding to the proton pump. Approximately 90% of metabolites are excreted in urine, with the remainder in feces.[32]

Stability Considerations

Rabeprazole exhibits significant stability challenges, particularly in acidic and aqueous environments. The drug degrades rapidly at pH values below 4, forming various degradation products including Rabeprazole thioether and sulfone derivatives. Moisture and temperature also critically affect stability. Formulations must incorporate:

- Enteric coating systems
- Moisture barrier coatings
- Desiccants in packaging
- Storage at controlled room temperature (15-30°C)
- Protection from light and moisture[44]

Pharmacology of DSR Components

Mechanism of Action of Domperidone

Domperidone functions as a peripheral dopamine D2 receptor antagonist, exerting its prokinetic effects through multiple mechanisms:

Dopamine Receptor Blockade

Domperidone selectively blocks dopamine D2 receptors in the gastrointestinal tract and chemoreceptor trigger zone (CTZ) of the area postrema. By antagonizing these receptors, it:

- Removes the inhibitory effect of dopamine on gastrointestinal smooth muscle
- Enhances acetylcholine release from enteric neurons
- Increases amplitude of esophageal and gastric peristaltic contractions
- Accelerates gastric emptying
- Increases lower esophageal sphincter (LES) pressure

Antiemetic Effects

The antiemetic action results from blocking dopamine receptors in the CTZ, located outside the blood-brain barrier. This provides effective control of nausea and vomiting without causing significant central nervous system effects such as sedation or extrapyramidal symptoms, which are common with centrally-acting dopamine antagonists like Metoclopramide.[21]

Effects on Prolactin

As a peripheral dopamine antagonist, Domperidone blocks dopamine receptors in the anterior pituitary gland, leading to increased prolactin secretion. While this can be therapeutically beneficial in some conditions (such as promoting lactation), it may cause adverse effects including galactorrhea and gynecomastia with prolonged use.[35]

Mechanism of Action of Rabeprazole

Rabeprazole, as a proton pump inhibitor, exhibits a sophisticated mechanism involving acid-catalyzed activation and irreversible enzyme inhibition:[34]

Activation Process

Following absorption from the small intestine, Rabeprazole is transported via systemic circulation to gastric parietal cells. The drug accumulates in the acidic secretory canaliculi of these cells where it undergoes acid- catalyzed conversion to its active sulfenamide form. This activation is pH-dependent, occurring optimally at pH <3.[17]

Proton Pump Inhibition

The activated sulfenamide form forms covalent disulfide bonds with cysteine residues (particularly Cys813 and Cys822) of the H+/K+-ATPase enzyme (proton pump) located on the secretory membrane of parietal cells. This irreversible binding inhibits the final step of gastric acid secretion, effectively blocking acid production regardless of the stimulus (histamine, gastrin, or acetylcholine).[34]

Duration of Action

Although Rabeprazole has a short plasma half-life (1-2 hours), its antisecretory effect persists for 24-48 hours because:

- The binding to proton pumps is irreversible.
- Recovery of acid secretion requires synthesis of new H+/K+-ATPase enzyme molecules
- The rate of enzyme regeneration determines the duration of acid suppression.[26]

Dose-Response Relationship

Rabeprazole demonstrates predictable dose-dependent inhibition of gastric acid secretion:

- 10 mg daily: Approximately 75% suppression of 24-hour gastric acidity
- 20 mg daily: Approximately 88% suppression of 24-hour gastric acidity
- Maximum acid suppression achieved within 2-3 days of once-daily dosing.[26]

Synergistic Effects in Combination

The combination of Domperidone and Rabeprazole provides complementary therapeutic benefits:

1. Comprehensive GERD Management: Rabeprazole addresses acid-related symptoms (heartburn, esophagitis), while Domperidone manages motility-related symptoms (regurgitation, bloating)

2. Enhanced Esophageal Clearance: Domperidone increases LES pressure and esophageal peristalsis, physically preventing reflux, while Rabeprazole reduces the acidity of any refluxed material

3. Improved Gastric Emptying: Domperidone accelerates gastric emptying, reducing the volume available for reflux, complementing Rabeprazole's acid suppression

4. Symptom Relief Optimization: The combination addresses a broader spectrum of GERD symptoms compared to either agent alone, potentially improving patient satisfaction and treatment adherence.[12]

Comparative Analysis of Drugs Used in DSR-Type Formulations

Comparison of Prokinetic Agents

While Domperidone is the most commonly used prokinetic agent in DSR formulations, several alternatives exist within the prokinetic class:

Domperidone vs. Metoclopramide Similarities:

- Both are dopamine D2 receptor antagonists
- Both exhibit prokinetic and antiemetic properties
- Similar efficacy in accelerating gastric emptying[13]

Differences:

Table no. 1: Parameters of Domperidone & Metoclopramide

Parameter	Domperidone	Metoclopramide
Blood-brain barrier penetration	Minimal	Significant
Central side effects	Rare	Common (sedation, anxiety, depression
Extrapyramidal symptoms	Very rare	Common (especially at higher doses)
Prolactin elevation	Moderate	Moderate
Cardiac effects	QTc prolongation (dose- dependent	Minimal
Preferred in	GERD, gastroparesis	Chemotherapy-induced nausea

Formulation Preference: Domperidone is generally preferred in DSR-type formulations due to its superior tolerability profile and lower incidence of CNS-related adverse effects, making it suitable for chronic use in GERD management.[13]

Domperidone vs. Mosapride

Table No. 2: Features of Mosapride & Domperidone Domperidone vs. Itopride

Feature	Mosapride	Domperidone
Mechanism of Action	Acts on 5-HT4 receptors	Blocks D2 (dopamine) receptors
Side Effects	Minimal dopaminergic effects; no prolactin elevation	Dopaminergic effects possible; prolactin elevation
Cardiac Safety	Better cardiac safety profile	Higher cardiac risk (QT prolongation concern)
Antiemetic Effect	Weaker antiemetic effect	Stronger antiemetic properties
Availability	Limited availability in some regions	Wider global availability

Itopride hydrochloride combines D2 receptor antagonism with acetylcholinesterase inhibition, providing dual prokinetic mechanisms.

Comparative Advantages:

- Itopride: Lower prolactin elevation, dual mechanism
- Domperidone: Stronger antiemetic effect, more established clinical data
- Both have similar prokinetic efficacy in comparative studies.[13]

Comparison of Proton Pump Inhibitors

DSR formulations could theoretically incorporate different PPIs instead of Rabeprazole. Understanding their comparative properties is essential:[11]

Rabeprazole vs. Omeprazole

Pharmacokinetic Differences:

Table no. 3: Parameters of Rabeprazole & Omeprazole

Parameter	Rabeprazole	Omeprazole
Onset of action	Faster (Day 1)	Slower (Day 3-5)
CYP2C19 dependence	Low	High
Pharmacokinetic variability	Lower	Higher (genetic polymorphism)
Food effect	Minimal	Moderate
Drug interactions	Fewer	More frequent

Clinical Implications: Rabeprazole's lower dependence on CYP2C19 metabolism provides more consistent acid suppression across diverse patient populations, including CYP2C19 poor metabolizers who respond inadequately to Omeprazole.[18]

Rabeprazole vs. Pantoprazole

Comparative Analysis:

- **Acid Stability**: Pantoprazole is more acid-stable than Rabeprazole
- **Activation Rate**: Rabeprazole activates more rapidly in acidic environment
- **Protein Binding**: Similar (both >95%)
- **Drug Interactions**: Pantoprazole has fewer cytochrome P450 interactions
- **Clinical Efficacy**: Comparable in GERD management

Formulation Consideration: Rabeprazole's faster activation provides quicker symptom relief, making it advantageous in combination products targeting acute symptom control.[11]

Rabeprazole vs. Esomeprazole

Esomeprazole, the S-isomer of Omeprazole, offers improved pharmacokinetic properties compared to its racemic predecessor.

Comparative Features:

- **Stereochemistry**: Esomeprazole (pure S-isomer) vs. Rabeprazole (achiral)
- **Acid Suppression**: Esomeprazole provides slightly higher acid suppression at equivalent doses

- **Metabolic Pathway**: Esomeprazole shows CYP2C19 dependence; Rabeprazole shows less
- **Healing Rates**: Similar in erosive esophagitis
- **Cost**: Rabeprazole is generally more cost-effective[11]

Selection Rationale for Rabeprazole in DSR

Rabeprazole is preferred in DSR formulations for several reasons:

1. Rapid onset of action provides quick symptom relief
2. Predictable pharmacokinetics across patient populations
3. Lower potential for drug-drug interactions
4. Established clinical efficacy and safety profile
5. Compatible with Domperidone in combination therapy
6. Cost-effectiveness compared to newer agents[33]

Quality Aspects and Analytical Methods

Official Compendia Standards

Both Domperidone and Rabeprazole sodium are included in major pharmacopoeias:

United States Pharmacopeia (USP):

- Provides monographs for both active ingredients
- Specifies identity tests, assay methods, and impurity limits
- Outlines dissolution requirements for solid dosage forms

British Pharmacopoeia (BP):

- Contains detailed specifications for raw materials
- Describes chromatographic methods for purity assessment
- Establishes limits for related substances

Indian Pharmacopoeia (IP):

- Includes specifications adapted to regional manufacturing practices
- Provides relevant analytical procedures[8.9,10]

Analytical Methods for Domperidone

Table no. 4: Analytical Methods for Domperidone

Analytical Method	Key Details	Applications
HPLC (High-Performance Liquid Chromatography)	• Most common method for quantification • C18 column • Mobile phase: acetonitrile + buffer (pH 3–6) • UV detection at 284 nm	Assay, dissolution testing, content uniformity
UV-Visible Spectrophotometry	• Simple and cost-effective • Detection wavelength: 284 nm	Routine analysis, raw material testing, formulation development
LC-MS/MS	• High sensitivity and specificity • Detects ng/mL concentrations • Suitable for biological matrices	Pharmacokinetic and bioavailability studies
Impurity Profiling	• HPLC with gradient methods • Monitors process-related and degradation impurities • Individual impurity limit: <0.1%	Quality control and regulatory compliance

Analytical Methods for Rabeprazole Sodium

Table no. 5: Analytical Methods for Rabeprazole Sodium Quality Control for Combination Products

Analytical Method	Key Details	Applications
HPLC Methods	• Reversed-phase chromatography • Mobile phase: phosphate buffer (pH 7–8) with acetonitrile or methanol • UV detection at 280–284 nm • Stability-indicating methods separate degradants	Assay, impurity analysis, stability studies
Dissolution Testing	• Essential for enteric-coated formulations • Acid stage: 2 hours in 0.1N HCl • Buffer stage: pH 6.8 • Criteria: <10% release in acid stage, >80% release in buffer stage	Performance evaluation of enteric-coated dosage forms
Chiral Analysis	• Not required • No chiral centers present	Differentiation from omeprazole-type PPIs
Degradation Studies	• Forced degradation: acid, alkali, oxidative, thermal, photolytic • Identifies thioether and sulfone degradation products •Stability-indicating method validation required	Stability assessment and method validation

DSR tablets present unique quality control challenges due to the combination of immediate-release Domperidone and enteric-coated Rabeprazole components:

Stratified Dissolution Testing:

- Separate quantification of both drugs at multiple time points

- Assessment of Domperidone immediate release profile

- Verification of Rabeprazole acid resistance and subsequent release

Content Uniformity:

- Individual analysis of both components
- Particular attention to coating uniformity for Rabeprazole granules
- Acceptance criteria as per USP/BP requirements

Stability Studies:

- ICH-guided stability protocols (accelerated and long-term)
- Monitoring both drugs and their degradation products
- Assessment of physical parameters (hardness, disintegration, dissolution)
- Packaging compatibility studies

Impurity and Degradation Monitoring:

- Simultaneous determination of impurities from both drugs
- Validation of specificity in presence of potential interactions
- Establishment of stability-indicating nature of methods.[37,44,45]

Formulation Challenges and Strategies

Domperidone, a BCS Class II drug with poor aqueous solubility, requires advanced solubility enhancement approaches such as solid dispersion technology using hydrophilic carriers (PEG, PVP, poloxamers) prepared by solvent evaporation, hot-melt extrusion, or spray drying, complexation with cyclodextrins to improve dissolution and stability, nanonization through wet milling or high-pressure homogenization to increase surface area, and lipid-based self-emulsifying drug delivery systems (SEDDS) that enhance and stabilize gastrointestinal absorption. In contrast, the acid-labile nature of Rabeprazole necessitates robust acid- protection strategies including pH-dependent enteric coating systems (Eudragit L/S, HP-55, cellulose acetate phthalate) with dissolution thresholds around pH 5.5–6.5, multi-layered coating designs, enteric-coated granulation with alkaline excipients and microencapsulation, and moisture-barrier coatings using hydrophobic polymers or waxes for long-term stability. For combined DSR formulations, Multiple Unit Particulate Systems (MUPS) offer superior performance by enabling independent release control of Domperidone (immediate- release) and Rabeprazole (enteric-coated pellets), ensuring uniform gastric distribution, minimizing dose dumping, improving bioavailability, and maintaining coating integrity during compression through the use of cushioning agents. Overall stability is further enhanced by protective packaging such as aluminum-aluminum blisters and desiccant-containing containers, formulation additives including antioxidants, alkaline buffering agents, and moisture scavengers, and defined storage conditions of 15–30 °C with protection from light and moisture, thereby ensuring product quality throughout its shelf life.

Clinical Applications and Therapeutic Outcomes

Domperidone–Rabeprazole DSR tablets are widely indicated in the management of gastroesophageal reflux disease (GERD), erosive and non-erosive reflux disease, gastritis associated with delayed gastric emptying, functional dyspepsia with acid-related symptoms, and as adjunctive therapy in Zollinger–Ellison syndrome, with additional benefits in post-operative gastroparesis, GERD in diabetic patients with motility disorders, and prophylaxis of NSAID-induced gastrointestinal complications. Multiple clinical studies have consistently demonstrated superior therapeutic outcomes of the combination therapy compared with Rabeprazole monotherapy, showing faster symptom relief (2–3 days vs. 4–5 days), improved control of heartburn, regurgitation and bloating, higher complete symptom resolution at four weeks, enhanced healing rates of erosive esophagitis (85–90% at eight weeks compared with 75–80%), sustained symptom control during maintenance therapy, and significantly improved quality-of-life scores including better sleep quality and patient satisfaction. The standard dosage consists of Domperidone 30 mg and Rabeprazole 20 mg administered once or twice daily, preferably 30 minutes before meals, for 4–8 weeks in acute therapy with longer maintenance in selected patients, while dose adjustments and careful monitoring are recommended in hepatic impairment, moderate renal

dysfunction, elderly patients, and pediatric use where safety data remain limited. The combination is generally well tolerated, with common adverse effects such as headache, gastrointestinal disturbances, dizziness and dry mouth, whereas serious but infrequent effects include QTc prolongation and endocrine disturbances related to Domperidone, long-term PPI-associated risks such as fractures, hematological abnormalities and Clostridium difficile infection, along with rare neurological reactions. Contraindications include hypersensitivity to either drug, prolactinoma, gastrointestinal obstruction or bleeding, moderate to severe hepatic impairment, concurrent use of potent CYP3A4 inhibitors, and pre- existing cardiac rhythm disorders, and clinically relevant drug interactions involve CYP3A4 inhibitors increasing Domperidone exposure, enzyme inducers reducing Rabeprazole efficacy, reduced absorption of pH-dependent drugs with PPIs, and potential interaction with antiplatelet agents such as clopidogrel.

Literature Review

Holtmann G. et al. (2006) demonstrated that the combination of Domperidone with proton pump inhibitors significantly improves symptom control in patients with gastroesophageal reflux disease (GERD) compared to PPI monotherapy. Their study highlighted that the prokinetic action of Domperidone enhances gastric emptying and reduces reflux episodes, while Rabeprazole provides potent and sustained acid suppression. The authors concluded that combination therapy offers superior therapeutic outcomes and improved patient compliance.

Humphries T. J. et al. (1999) evaluated the pharmacological profile of Rabeprazole and reported its rapid onset of action, predictable pharmacokinetics, and lower dependence on CYP2C19 metabolism when compared with other proton pump inhibitors. The study emphasized that these characteristics make Rabeprazole particularly suitable for combination therapy in acid-related disorders. The findings suggested that Rabeprazole provides consistent acid suppression across diverse patient populations.

Barone J. A. et al. (1999) investigated the clinical properties of Domperidone as a peripheral dopamine D_2 receptor antagonist and demonstrated its effectiveness in enhancing gastrointestinal motility with minimal central nervous system adverse effects. The authors highlighted Domperidone's favorable safety profile and its important role in managing nausea, vomiting, and motility-related symptoms in GERD patients.

Prakash A. et al. (2012) reviewed the rationale for fixed-dose combination therapy in GERD management and reported that Domperidone–Rabeprazole formulations provide synergistic therapeutic benefits by addressing both acid suppression and gastric motility disorders. The authors emphasized improved healing rates of erosive esophagitis, faster symptom relief, and better quality-of-life outcomes in patients receiving combination therapy.

Sharma P. et al. (2004) compared various prokinetic agents and concluded that Domperidone is generally preferred in GERD treatment due to its superior tolerability profile and lower incidence of central nervous system side effects compared with metoclopramide. The study supported the continued use of Domperidone in long-term GERD management.

Dekkers C. P. et al. (2011) analyzed the impact of CYP2C19 genetic polymorphism on the efficacy of proton pump inhibitors and demonstrated that Rabeprazole exhibits minimal variability in therapeutic response among different patient populations. The authors concluded that Rabeprazole ensures consistent acid suppression and enhances the reliability of combination therapy in GERD treatment.

Future Perspectives and Emerging Trends

Future development of Domperidone–Rabeprazole formulations is increasingly focused on advanced drug delivery technologies, including nanoparticulate systems such as nanosuspensions and nanocrystals that enhance bioavailability, enable targeted gastric mucosal delivery, and improve stability; 3D printing technology offering personalized dosing, complex multilayer dosage structures with precise drug loading, and on-demand manufacturing; and smart drug delivery platforms utilizing pH-responsive polymers, gastroretentive systems, and mucoadhesive formulations to achieve site-specific and prolonged therapeutic action. Ongoing research is also exploring alternative combination therapies incorporating newer pharmacological agents such as vonoprazan, a potassium-competitive acid blocker with rapid and potent acid suppression independent of pH, safer and more selective prokinetic agents including 5-HT4 agonists like prucalopride and velusetrag as potential replacements for Domperidone, and alginate-based raft-forming systems that provide immediate mechanical relief while complementing pharmacological acid suppression. In parallel, personalized medicine strategies are being developed through pharmacogenomic profiling, particularly CYP2C19 genotyping to optimize PPI dosing and identify patients requiring alternative therapies, along with biomarker-guided treatment approaches using esophageal pH monitoring and gastric emptying studies to predict therapeutic response and individualize therapy. From a regulatory and development standpoint, the adoption of Quality by Design (QbD) principles, establishment of design spaces for critical formulation parameters, risk-based quality management, harmonization of international regulatory guidelines including ICH standards for combination products, standardized bioequivalence requirements, and strengthened post-marketing surveillance

frameworks are expected to significantly enhance product consistency, safety, and global regulatory acceptance.

Summary & Conclusion

DSR tablets, combining Domperidone and Rabeprazole, represent a significant advancement in the management of gastroesophageal reflux disease and related gastrointestinal disorders. This comprehensive review has examined the pharmacological profiles, physicochemical properties, quality aspects, and comparative analysis of drugs used in these formulations.[1]

The synergistic combination of a prokinetic agent (Domperidone) and a proton pump inhibitor (Rabeprazole) addresses both the mechanical and chemical components of GERD pathophysiology. Domperidone's ability to enhance gastric motility and increase lower esophageal sphincter pressure complements Rabeprazole's potent acid suppression, providing comprehensive symptom control superior to monotherapy.[12]

However, successful formulation of DSR tablets presents significant challenges. The poor aqueous solubility of Domperidone necessitates solubility enhancement strategies, while the acid-labile nature of Rabeprazole requires sophisticated enteric coating technologies. Advanced formulation approaches such as MUPS technology have addressed these challenges, enabling the development of stable, efficacious combination products.[5]

Quality control of DSR tablets demands rigorous analytical methods capable of simultaneously determining both components and their degradation products. Stability-indicating HPLC methods, coupled with appropriate dissolution testing methodologies, ensure product quality throughout shelf life.[37]

Comparative analysis reveals that while alternative prokinetic agents (Metoclopramide, Mosapride, Itopride) and other PPIs (Omeprazole, Pantoprazole, Esomeprazole) exist, the Domperidone-Rabeprazole combination offers an optimal balance of efficacy, safety, and pharmacokinetic predictability. Domperidone's peripheral selectivity minimizes central nervous system side effects, while Rabeprazole's reduced dependence on CYP2C19 polymorphism ensures consistent therapeutic outcomes across diverse patient populations.[13,18]

Clinical evidence supports the superior efficacy of combination therapy in achieving faster symptom relief, higher healing rates, and improved quality of life compared to monotherapy. The safety profile is generally favorable, though clinicians must remain vigilant regarding potential cardiac effects of Domperidone and long-term risks associated with PPI therapy.[12]

Future developments in DSR-type formulations will likely focus on novel drug delivery technologies, including nanoparticulate systems, 3D-printed dosage forms, and smart delivery platforms. The emergence of newer agents such as potassium-competitive acid blockers and selective 5-HT4 agonists may lead to next- generation combination products with enhanced safety and efficacy profiles. Additionally, personalized medicine approaches incorporating pharmacogenomic data will enable optimization of therapy for individual patients.[50]

In conclusion, DSR tablets represent a well-established, evidence-based therapeutic option for GERD management. Continued research into formulation optimization, quality enhancement, and novel combination strategies will further improve outcomes for patients suffering from acid-reflux disorders. The integration of Quality by Design principles in development and manufacturing ensures consistent product quality, while ongoing pharmacovigilance safeguards patient safety. As our understanding of GERD pathophysiology evolves and new therapeutic agents emerge, the principles established through DSR tablet development will guide future innovations in combination therapy for gastrointestinal disorders.[45]

Acknowledgments

The authors acknowledge the extensive pharmaceutical literature and compendia that have contributed to the compilation of this comprehensive review. This work synthesizes information from multiple authoritative sources to provide a thorough understanding of DSR tablet formulations, their components, and clinical applications.

REFERENCES

1. **Remington: The Science and Practice of Pharmacy (22nd Edition). Pharmaceutical Press, London, 2013.** - Comprehensive pharmaceutical sciences reference covering drug properties, formulation principles, and quality control.
2. **Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th Edition). McGraw-Hill Education, 2018.** - Authoritative pharmacology textbook detailing mechanisms of action, pharmacokinetics, and therapeutic applications.
3. **Martindale: The Complete Drug Reference (39th Edition). Pharmaceutical Press, London, 2017**. - Extensive drug

monographs including physicochemical properties, pharmacology, and clinical use.
4. **Handbook of Pharmaceutical Excipients (8th Edition). Pharmaceutical Press and American Pharmacists Association, 2017.** - Reference for excipient properties, compatibility, and applications in formulation development.
5. **Aulton's Pharmaceutics: The Design and Manufacture of Medicines (5th Edition). Churchill Livingstone, 2017**. - Comprehensive coverage of pharmaceutical formulation, manufacturing, and quality assurance.
6. **Modern Pharmaceutics (5th Edition), Volume 1 & 2. Edited by Gilbert S. Banker and Christopher T. Rhodes. CRC Press, 2002**. - Detailed exploration of pharmaceutical dosage forms and drug delivery systems.
7. **Pharmaceutical Preformulation and Formulation**: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form (2nd Edition). Mark Gibson. Informa Healthcare, 2009. - Practical guidance on preformulation studies and formulation development.
8. **The United States Pharmacopeia (USP 44-NF 39). United States Pharmacopeial Convention, 2021.** - Official compendia standards for drug substances and dosage forms.
9. **British Pharmacopoeia (BP 2022). The Stationery Office, London, 2022.** - Official quality standards and analytical methods for pharmaceuticals.
10. **Indian Pharmacopoeia (IP 2018). Indian Pharmacopoeia Commission, Ghaziabad, 2018.** - National pharmacopoeial standards for drug substances and formulations. **Journal Articles and Research Papers**
11. Robinson, M., et al. "The comparative efficacy and safety of rabeprazole versus proton pump inhibitors in GERD treatment: A systematic review." **Alimentary Pharmacology & Therapeutics**, 2005; 21(12): 1381- 1391.
12. Holtmann, G., et al. "Efficacy of domperidone in combination with PPI therapy for GERD management: A randomized controlled trial." **American Journal of Gastroenterology**, 2006; 101(6): 1313-1319.
13. Sharma, P., et al. "Comparative study of prokinetic agents in gastroesophageal reflux disease." **Journal of Clinical Gastroenterology**, 2004; 38(8): 642-648.
14. Tack, J., et al. "Role of prokinetic agents in the management of gastroesophageal reflux disease." **Gut**, 2002; 51(Suppl 1): i25-i29.
15. Pantoflickova, D., et al. "Acid inhibition on the first day of dosing: Comparison of four proton pump inhibitors." **Alimentary Pharmacology & Therapeutics**, 2003; 17(12): 1507-1514.
16. Katz, P.O., et al. "Guidelines for the diagnosis and management of gastroesophageal reflux disease." **American Journal of Gastroenterology**, 2013; 108(3): 308-328.
17. Miwa, H., et al. "Pharmacologic characterization of rabeprazole sodium in comparison with omeprazole." **Digestive Diseases and Sciences**, 2009; 54(2): 261-268.
18. Dekkers, C.P., et al. "Clinical implications of CYP2C19 genotypic polymorphism on proton pump inhibitor efficacy." **Drug Metabolism and Pharmacokinetics**, 2011; 26(4): 315-325.
19. Humphries, T.J., et al. "Rabeprazole: Pharmacology and clinical experience." **Drugs**, 1999; 58(Suppl 2): 1-10.
20. Barone, J.A., et al. "Domperidone: A peripherally acting dopamine2-receptor antagonist." **Annals of Pharmacotherapy**, 1999; 33(4): 429-440.
21. Reyntjens, A., et al. "Domperidone in the treatment of gastroesophageal reflux." **Postgraduate Medical Journal**, 1979; 55(Suppl 1): 11-14.
22. Champion, M.C., et al. "Domperidone: A review of its properties and therapeutic use in gastrointestinal disorders." **Drugs**, 1986; 31(4): 312-334.
23. Prakash, A., et al. "Fixed-dose combination therapy for gastroesophageal reflux disease: Rationale and evidence." **Therapeutic Advances in Chronic Disease**, 2012; 3(4): 163-172.
24. Galmiche, J.P., et al. "Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride." **Alimentary Pharmacology & Therapeutics**, 1997; 11(4): 765- 773.
25. Talley, N.J., et al. "Efficacy of omeprazole in functional dyspepsia: Double-blind, randomised, placebo- controlled trials." **British Medical Journal**, 1998; 317(7154): 1397-1400.
26. Kahrilas, P.J., et al. "The effect of rabeprazole on gastric acid secretion and esophageal acid exposure in patients with gastroesophageal reflux disease." **American Journal of Gastroenterology**, 2000; 95(10): 2795- 2803.
27. Miner, P., et al. "Rabeprazole in non-erosive gastroesophageal reflux disease: A randomized placebo- controlled trial." **American Journal of Gastroenterology**, 2002; 97(6): 1332-1339.
28. Scholten, T., et al. "The effect of rabeprazole 20 mg versus omeprazole 20 mg on 24-hour intragastric pH in patients with gastroesophageal reflux disease." **Alimentary Pharmacology & Therapeutics,** 2000; 14(10): 1301-1307.
29. Cicala, M., et al. "Proton pump inhibitors resistance, the real challenge in gastro-esophageal reflux disease." **World Journal of Gastroenterology**, 2013; 19(39): 6529-6535.
30. Shakeri-Nejad, K., et al. "Pharmacokinetic interaction study of domperidone with ketoconazole and erythromycin." **Clinical Pharmacokinetics**, 2002; 41(Suppl 1): 31-37.
31. Huang, J., et al. "Pharmacokinetics of domperidone and its metabolites in healthy Chinese subjects."
European Journal of Clinical Pharmacology, 2007; 63(3): 279-285.
32. Yasuda, S., et al. "Comparative pharmacokinetics and pharmacodynamics of rabeprazole and other proton pump inhibitors."

European Journal of Clinical Pharmacology, 2001; 57(6-7): 485-495.
33. Cheer, S.M., et al. "Rabeprazole: A pharmacoeconomic review of its use in acid-related disorders." **Pharmacoeconomics**, 2003; 21(13): 955-988.
34. Sachs, G., et al. "Pharmacology of proton pump inhibitors." **Current Gastroenterology Reports**, 2006; 8(6): 528-534.
35. Ward, R.M., et al. "Development of domperidone for gastrointestinal applications." **Expert Opinion on Investigational Drugs**, 2000; 9(11): 2613-2620.
36. Prakash, A., et al. "Influence of pharmaceutical variables on in vitro drug release from domperidone tablets." **Dissolution Technologies**, 2008; 15(4): 14-19.
37. Sharma, V.K., et al. "Quality control aspects of combination drug products containing PPI and prokinetic agents." **Journal of Pharmaceutical and Biomedical Analysis**, 2010; 52(3): 321-329.
38. Patel, D., et al. "Development and validation of stability-indicating HPLC method for simultaneous determination of domperidone and rabeprazole in combined dosage form." **Journal of Chromatographic Science**, 2011; 49(10): 774-778.
39. Reddy, B.P., et al. "Development and validation of RP-HPLC method for simultaneous estimation of domperidone and rabeprazole in pharmaceutical dosage forms." **Analytical Chemistry: An Indian Journa**l, 2010; 9(2): 146-152.
40. Thangabalan, B., et al. "Simultaneous determination of domperidone and rabeprazole in combined dosage forms by UV spectrophotometric method." **International Journal of ChemTech Research**, 2010; 2(1): 464- 467.
41. Vetrichelvan, T., et al. "Development and validation of HPLC method for determination of domperidone and rabeprazole in solid dosage forms." **Indian Journal of Pharmaceutical Sciences**, 2007; 69(5): 670-673.
42. Zhao, W., et al. "Solid dispersion in the development of a domperidone tablet." **Asian Journal of Pharmaceutical Sciences**, 2012; 7(1): 35-41.
43. Sweetman, S.C., editor. **"Domperidone and Rabeprazole monographs**." In: Martindale: The Complete Drug Reference, 39th edition. Pharmaceutical Press, London, 2017.
44. ICH Harmonised Tripartite Guideline. **"Stability Testing of New Drug Substances and Products Q1A(R2)."** International Conference on Harmonisation, 2003.
45. ICH Harmonised Tripartite Guideline. **"Pharmaceutical Development Q8(R2)."** International Conference on Harmonisation, 2009.
46. FDA Guidance for Industry**. "Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions - Annex on Dissolution Test General Chapter."** U.S. Food and Drug Administration, 2011.
47. EMA Guideline**. "Development Pharmaceutics for Oral Dosage Forms."** European Medicines Agency, 2006.
48. CDSCO Guidelines. **"Requirements for Fixed Dose Combinations."** Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare, Government of India, 2016.
49. WHO Technical Report Series. **"Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability."** World Health Organization, 2017; No. 1003.
50. Sjögren, E., et al. "In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim." **European Journal of Pharmaceutical Sciences**, 2013; 49(4): 679-698.

How to cite this article:
Raj A. Sharma et al. Ijppr.Human, 2026; Vol. 32 (4): 412-425.
Conflict of Interest Statement: All authors have nothing else to disclose.